*  Multiple electrode aggregometry
cAMP inhibits platelet aggregation, and decreased amounts of cAMP in platelets lead to platelet aggregation. The PGE1 reagent ... Binding of fibrinogen to GPIIb/IIIa receptors leads to platelet-to-platelet bridges and results in platelet aggregation. ... TXA2 increases platelet aggregation, promotes degranulation and stimulates platelet activation. Inhibition of COX1, as with ... The P2Y1 receptor is required for ADP-induced platelet activation, but is not sufficient for a full platelet aggregation in ...
*  Thromboregulation
... but platelet aggregation must grow exponentially to form a platelet thrombus and prevent blood loss. Platelet aggregation ... Some thromboregulators enhance platelet aggregation and some others inhibit the process. Platelet aggregation plays a critical ... Platelet aggregation is fundamental to repair vascular damage and the initiation of the blood thrombus formation. The ... Kistrin is a protein inhibitor of platelet aggregation. It belongs to the homologous family of glycoprotein IIb-IIa antagonists ...
*  Prasugrel
Maximum platelet inhibition was about 80%. Mean steady-state inhibition of platelet aggregation was about 70% following three ... Increasing platelet inhibition could increase bleeding risk. The relationship between inhibition of platelet aggregation and ... Platelet aggregation gradually returns to baseline values over five to 9 days after discontinuation of prasugrel, this time ... Following a 60-mg loading dose of the drug, about 90% of patients had at least 50% inhibition of platelet aggregation by one ...
*  Antithrombotic
Antiplatelet drugs limit the migration or aggregation of platelets. Anticoagulants limit the ability of the blood to clot. ...
*  Ristocetin-induced platelet aggregation
The ristocetin-induced platelet aggregation (RIPA) is an ex vivo assay for live platelet function. It measures platelet ... it causes agglutination of fixed platelets or initiates the initial agglutination phase of aggregation of live platelets. The ... Ristocetin cofactor assay uses platelet-poor plasma (with vWF but no platelets) and adds ristocetin and exogenous formalin- ... CS1 maint: Multiple names: authors list (link) Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch ...
*  Pamicogrel
"Pamicogrel inhibits platelet aggregation". Inpharma Weekly. 1272 (1): 11. January 2001. doi:10.2165/00128413-200112720-00021. ... Pamicogrel is a cyclooxygenase inhibitor that was under development for its anti-platelet-aggregation effects. Light P ( ...
*  Waldenström's macroglobulinemia
Platelet aggregation studies are optional. Serum protein electrophoresis results indicate evidence of a monoclonal spike but ... A low white blood cell count, and low platelet count in the blood may be observed. A low level of neutrophils (a specific type ... According to the model, factors predicting reduced survival are: Age > 65 years Hemoglobin ≤ 11.5 g/dL Platelet count ≤ 100×109 ... "Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation". Blood. 115 (22): ...
*  Alcohol and cardiovascular disease
... moderate ethanol consumption on human platelet aggregation in platelet-rich plasma and whole blood". Alcohol. Clin. Exp. Res. ... Alcohol decreases thrombosis (blood clotting). A. It reduces platelet aggregation. B. It reduces fibrinogen (a blood clotter). ...
*  Indobufen
... is a platelet aggregation inhibitor. It acts as a reversible cyclooxygenase inhibitor. The Merck Index, 12th Edition ...
*  Picotamide
... is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor ...
*  Ditazole
... is a platelet aggregation inhibitor. It is marketed in Spain and Portugal under the trade name Ageroplas. Martindale's ...
*  Vitamin B6
The result is inhibition of platelet aggregation. Vitamin B6 is widely distributed in foods in both its free and bound forms. ...
*  Gaseous signaling molecules
CO inhibits blood platelet aggregation and adhesion. CO may play a role as potential therapeutic agent. In mammals, carbon ... platelet aggregation, and leukocyte adhesion to the endothelium. Humans with atherosclerosis, diabetes, or hypertension often ...
*  Biological functions of carbon monoxide
CO inhibits blood platelet aggregation and adhesion. CO may play a role as potential therapeutic agent. In mammals, carbon ...
*  Terutroban
It blocks thromboxane induced platelet aggregation and vasoconstriction. Hennerici, M. G.; Bots, M. L.; Ford, I.; Laurent, S.; ...
*  Dihydroxy-E,Z,E-PUFA
10R,17S-diHDHA and to slightly lesser degrees 10R,17S-diHDHA and PDX inhibit the human platelet aggregation response to ... These E,Z,E PUFA are 20- to 100-fold stronger in inhibiting human platelet aggregation than two mono-hydroxyl-containing ... Croset M, Lagarde M (1983). "Stereospecific inhibition of PGH2-induced platelet aggregation by lipoxygenase products of ... potently inhibit blood platelet aggregation". FASEB Journal : Official Publication of the Federation of American Societies for ...
*  Cytochalasin B
... inhibits glucose transport and platelet aggregation. It blocks adenosine-induced apoptotic body formation ...
*  Frostbite
Platelet aggregation is another possible mechanism of injury. Blisters and spasm of blood vessels (vasospasm) can develop after ...
*  Vorapaxar
... a new class of anti-platelet drug. It functions by inhibiting thrombin-related platelet aggregation. This mechanism works by a ... Unlike many other medication, vorapaxar does not affect ADP-mediated platelet aggregation, coagulation parameters, or bleeding ... Vorapaxar is a new anti-platelet drug that is part of the PAR-1 antagonist family, ... different pathway than other anti-platelet medications such as aspirin and P2Y12 inhibitors. ...
*  Joshua B. Bederson
"Acute microvascular platelet aggregation after subarachnoid hemorrhage (SAH)." J Neurosurg 2005. 102(6) 1094- 1100. PMID ...
*  Bencyclane
... is an antispasmodic, vasodilator & platelet aggregation inhibitor. https://books.google.co.uk/books?isbn=1475720858 ...
*  Phosphodiesterase 2
PDE3 is an important player in platelet aggregation. It has been reported that higher concentration of cGMP causes inhibition ... Interplay between those two functions seems to mediate an opposing regulation of cAMP in platelets (See review article ). PDE2 ... See review article.) PDE2 is expressed in various tissues, for example: adrenal medulla, brain, heart, platelet, macrophages ... that PDE2 might play an important role in the regulation of elevated intracellular concentrations of cAMP and cGMP in platelets ...
*  Glycoprotein IIb/IIIa inhibitors
They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the ... surface of the platelets. They may also be used to treat acute coronary syndromes, without percutaneous coronary intervention, ...
*  Treprostinil
... also inhibits platelet aggregation and smooth muscle proliferation. The pharmacokinetics of continuous ... Because of treprostinil's inhibiting effect on platelet aggregation, there is an increased risk of bleeding, especially among ... which inhibited platelet aggregation. PG-X, which later would become known as prostacyclin, was 30 times more potent than any ... isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation". ...
*  Nicergoline
Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases ... Migraines of vascular origin Coadjutant therapy in clinical situations accompanied by platelet hyper-aggregability, arterial ...
*  Russellysin
... platelet aggregation inhibitor)-like and C-type lectin-like domains". J. Biol. Chem. 267: 14109-14117. PMID 1629211. ...
*  MED13
Tuchin DA, Erve PR, Schumer W (1976). "Prevention of endotoxin--induced irreversible platelet aggregation in vitro". Surgical ...